surface plasmon resonance ͉ antibody engineering ͉ directed evolution ͉ yeast display ͉ antibody biomanufacture
Immunoglobulin G plays a vital role in adaptive immunity and antibody-based therapy through engagement of its Fc region by the Fc␥ receptors (Fc␥Rs) on immune cells. In addition to specific protein-protein contacts, N-linked glycosylation of the IgG Fc has been thought to be essential for the recognition of Fc by Fc␥R. This requirement for the N-linked glycan has limited biomanufacture of therapeutic antibodies by restricting it to mammalian expression systems. We report here aglycosylated Fc domain variants that maintain engagement to Fc␥Rs, both in vitro and in vivo, demonstrating that Fc glycosylation is not strictly required for the activation of immune cells by IgG. These variants provide insight into how the N-linked glycan is used biologically in the recognition of Fc by Fc␥Rs, as well as represent a step toward the production in alternative expression systems of antibody-based therapeutics capable of eliciting immune effector functions.
surface plasmon resonance ͉ antibody engineering ͉ directed evolution ͉ yeast display ͉ antibody biomanufacture F c gamma receptor (Fc␥R) engagement is essential to the function of IgG in both immunity (1) and in antibody-based therapy (2, 3) . IgGs act as the adaptor between a pathogen and the immune response by simultaneously binding antigen through their variable regions and activating an immune response through interaction of conserved Fc regions with Fc␥Rs on cells of the immune system. The human Fc␥R (hFc␥R) family consists of the activating receptors Fc␥RI, Fc␥RIIA, and Fc␥RIIIA, and the inhibitory receptor Fc␥RIIB. While Fc␥RI binds IgG with high affinity (nanomolar binding constants), Fc␥RIIA, Fc␥RIIB, and Fc␥RIIIA bind IgG with micromolar affinity, becoming activated only via avid multivalent interactions with opsonized antigen (1) . The binding of IgG to Fc␥R is highly sensitive to the presence of glycosylation at a single N-linked glycosylation site at asparagine 297 (N297) in its CH2 domain (4, 5) , with a loss of binding to the low-affinity Fc␥Rs observed in N297 point mutants (6, 7) , enzymatic Fc deglycosylation (8) , recombinant IgG expression in the presence of the N-linked glycosylation-inhibitor tunicamycin (9) , or expression in bacteria (10, 11) . In addition, the nature of the carbohydrate attached to N297 modulates the affinity of the Fc␥R interaction (12, 13) . The sensitivity of Fc␥R binding to specific glycoforms has limited therapeutic antibody biomanufacture to mammalian expression systems, and has led to the development of glycosylationengineered mammalian cell lines (13, 14) and microbial strains with humanized glycosylation (15) as methods of enhancing antibody cytotoxicity.
In crystal structures of the complex, Fc␥R/Fc contact is mediated not only by protein-protein contacts, but also by specific interactions with the glycan on the Fc that are proposed to contribute to binding affinity (16, 17 (20) . In the IgG 1 Fc:Fc␥RIII complex, extensive contacts are made by both chains of the IgG 1 hinge region, with additional receptor contacts made by the B/C loop, F/G loop, and both side chains and glycosylation of the CЈ/E loop of the CH2 domain (16, 17) [ Fig. 1A , supporting information (SI) Fig. S1 ]. It is particularly striking that this loop plays a part in receptor recognition through both direct side chain contacts as well as in encoding information for a critical posttranslational modification.
In the present study, we reasoned that by optimizing the protein-protein interactions about the CЈ/E loop:Fc␥R interface at the expense of glycosylation, we could identify aglycosylated IgG 1 variants that maintain engagement to Fc␥Rs. Here, we demonstrate that a small subset of substitutions at both N297 and T299 of the glycosylation motif lead to aglycosylated Fcs that maintain engagement of Fc␥Rs, and in a particular example are active in vivo. Such aglycosylated antibodies would be facile templates for further efforts to engineer Fc-effector functions and potentially enable a far wider range of options for therapeutic antibody biomanufacture.
Results
Screening for Aglycosylated Fc Variants that Bind Fc␥RIIA. To determine if glycosylation of the Fc was an absolute requirement for Fc␥R engagement by hIgG 1 , we constructed saturation mutagenesis libraries at the Fc CЈ/E loop and screened them by displaying the full-length IgG variants on the yeast cell surface (Fig. S2) . In this display system, the femtomolar affinity fluorescein-binding 4m5.3 single-chain antibody (21) was reformatted as a hIgG 1 , allowing 4m5.3 hIgG 1 library variants to be captured on fluorescein-labeled yeast from which they are secreted, by using a cell-surface secretion capture assay (22) in conjunction with an engineered leader sequence that allows for the improved secretion of fully-assembled hIgG 1 from S. cerevisiae (Rakestraw JA, S.L.S., Piatesi A, Antipov E, K.D.W., unpublished data). Three saturation libraries centered about the CЈ/E loop-theoretically encoding all amino acid combinations at residues 296-299, 297-299, and 297-300-were pooled and screened for binding to fluorophore-labeled tetramers of a soluble form of the Fc␥RIIA 131R allele by multiple rounds of FACS.
Using this screening strategy, in addition to glycosylated variants and the wild type (WT) clone, mutants lacking the canonical Asn-X-Ser/Thr N-linked glycosylation motif were enriched from the CЈ/E loop libraries for binding to Fc␥RIIA (Fig.  1B) . After two rounds of screening, three aglycosylated motifs were identified: the double mutants S298G/T299A and S298G/ T299G, and the single mutant T299A. After a third round of screening at increased stringency, the sublibrary was dominated by the S298G/T299A variant, suggesting it as the highest-affinity Fc␥RIIA binding motif in the library (Fig. 1C) .
To study the contributions of the S298G and T299A mutations to receptor binding, a series of point mutants were constructed, secreted from yeast, and assayed for their ability to bind to Fc␥RIIA 131R (Fig. 1D ). Both the S298G and T299A mutations alone retain binding to Fc␥RIIA at comparable or increased levels to WT IgG 1 , and the S298G mutation in the aglycosylated T299A background yields a variant capable of binding Fc␥RIIA to a much greater extent. The S298G/T299A double mutant is incapable of rescuing binding in the N297Q, N297D, and N297A backgrounds, suggesting there is a strong requirement for asparagine at position 297 for Fc␥RIIA binding, even in the absence of conjugated carbohydrate, a finding consistent with its conservation in the initial library screen. S298G/T299A Is Aglycosylated and Binds to Fc␥Rs. To confirm that the potential aglycosylated motifs identified from the yeastbased screen indeed lacked the N-linked glycan and were capable of engaging Fc␥Rs, WT, S298G/T299A, and the nonreceptor binding N297Q aglycosylated control were expressed and purified from HEK 293 cells. Both N297Q and S298G/T299A exhibit increased mobility by reducing SDS/PAGE ( Fig. 2A) and, critically, are not recognized by the mannose-specific lectin LCA (Fig. 2B) , consistent with the expected absence of N-linked glycosylation. Surface plasmon resonance measurements show that S298G/T299A binds to both Fc␥RIIA alleles, Fc␥RIIA 131R and Fc␥RIIA 131H , and to Fc␥RIIB; however, this mutant does not bind to Fc␥RIIIA nor the complement component C1q, and binding to Fc␥RI was weakened by 10-fold. (Fig. 2C) 131R , is expressed as a transgene, thus maintaining cell-type expression appropriate for the human transgene (23) . Mice with this genotype were treated with WT, N297A, and S298G/T299A 6A6 hIgG 1 purified from HEK 293 cells and the extent of platelet clearance measured over time (Fig. 3) . After 4 hours, S298G/ T299A-6A6-treated mice (n ϭ 3) showed a statistically significant drop in platelet count when compared to those treated with N297A-6A6 or PBS, exhibiting a response that was comparable to WT-6A6 and demonstrating the ability of S298G/T299A to productively engage Fc␥RIIA in vivo and result in platelet clearance.
Model of S298G/T299A-Fc␥RIIA Interaction. To explore the structural basis for Fc␥R binding of this aglycosylated Fc domain variant, we constructed homology models of Fc:Fc␥RIIA complexes based on the previously solved structures of the IgG 1 Fc, the Fc␥RIIA structure (24) , and the Fc:Fc␥RIII complex (17) (Fig. 4) . Three features emerge from this modeling. First, in the model of the WT interaction, there is only limited interaction between the two N-linked glycans and Fc␥RIIA (see Fig. 4A ). The asymmetric nature of the IgG 1 Fc:Fc␥RIIA interaction predicts that the glycan attached to the B chain of the Fc dimer may interact with residues K117, T119, F121, S126, and F129 of the receptor, whereas the glycan attached to the other chain (the A chain) does not make contact with Fc␥RIIA. 1 or the aglycosylated variants N297A and S298G/T299A. Mice (n ϭ 3) were injected with either antibody or PBS control and bled at 4, 24, and 72 h after injection. Normalized to platelet counts before injection, counts 4 h following injection of the 6A6 antibodies were 15.8 Ϯ 13.9% for WT, 39.5 Ϯ 5% for S298G/T299A, 71.0 Ϯ 6.1% for N297A, and 85.7 Ϯ 11.0% for those treated with PBS only. S298G/ T299A-treated mice displayed a statistically significant difference in platelet reduction compared to N297A (P ϭ 0.017) and PBS (P ϭ 0.002), but not a statistically significant difference compared to WT (P ϭ 0.068). interaction. Aglycosylated N297 has the potential to make hydrogen bond interactions across the interface with S126 of the receptor (see Fig. 4B ). These interactions may be mediated by a bridging water molecule that can be observed nearby in an unbound Fc␥RIIA crystal structure (24) . Replacement of N297 with glutamine or alanine disrupts this interaction (and fails to make similar, stabilizing ones) and is consistent with the observed absence of binding for such mutants (see Fig. 1D and Fig.  S5A ). Interestingly, replacement with aspartic acid may be able to make a similar interaction; however the greater desolvation penalty of the charged side chain upon Fc␥R binding likely results in the reduced binding of this variant.
Finally, the intermolecular interaction between the aglycosylated S298G/T299A mutant and Fc␥RIIA includes a salt bridge formed between D265 on the B chain of the Fc dimer and K117 on the Fc␥R. In the WT structure, this interaction is shielded from solvent by the oligosaccharide chain (see Fig. 4C ). In the aglycosylated S298G/T299A mutant, this salt bridge is exposed to the solvent (see Fig. 4D ), which nearly halves the screened electrostatic interaction energy compared to WT (Ϫ5 kcal/mol versus Ϫ10 kcal/mol). However, this effect is more than compensated in the S298G/T299A mutant by a reduced desolvation penalty (25) , a measure of the loss of electrostatic interactions with solvent upon binding, resulting in an overall stabilized structure. This effect is illustrated (see Fig. 4 E and F) by a reduction in the residual electrostatic potential present on D265(B) in the mutant compared to the WT; similarly, Fig. 4 also shows the S298G mutation results in a reduced desolvation penalty that contributes to the stability of the mutant complex. Thus, the predictions made by this homology model provide a hypothetical mechanism for the stability of the aglycosylated Fc:Fc␥R complex, resulting from hydrogen bonding and electrostatic interactions altered in the aglycosylated mutant.
Aglycosylated Fc Variants that Bind Fc␥RIIIA.
To evaluate the contribution of individual sidechains in the CЈ/E loop to Fc␥R engagement, as well as the nature of the specificity between Fc␥RIIA and Fc␥RIIIA seen in S298G/T299A, we constructed the full set of single-point mutations at positions 297, 298, and 299, and assayed yeast-secreted IgG variants for binding to both Fc␥RIIA and Fc␥RIIIA (see Fig. S5 ). Side-chain scanning of 297 and 299 revealed additional mutations that remove the glycosylation motif but retain residual weak receptor binding: T299H to Fc␥RIIA, and N297D and N297H to Fc␥RIIIA 176V (see Fig. S5 A and C) . T299A is the only aglycosylated mutant identified that displays dual specificity, exhibiting improved binding to Fc␥RIIA while retaining moderate binding to the Fc␥RIIIA 176V allele. Interestingly, the nature of the side chains at position 299, and not just glycosylation, greatly impacts receptor binding, as the yeast-expressed glycosylated T299S mutant binds all receptors to a much lesser extent than the WT Fc.
In contrast to positions 297 and 299, where mutations largely disrupt the N-linked glycosylation motif Asn-X-Ser/Thr, multiple substitutions in a glycosylated Fc background are tolerated at position 298 (see Fig. S5B ). Fc␥RIIA binding is much more sensitive to substitution at position 298, with only glycine (S298G) maintaining a level of binding that is comparable to WT. In contrast, Fc␥RIIIA tolerates an array of substitutions at position 298, and the data highlight potential mutations for engineering Fc␥RIIIA versus Fc␥RIIA/Fc␥RIIB specificity, such as the previously identified S298A and S298N mutations (6, 26) . Only S298G maintained engagement to both Fc␥RIIA and Fc␥RIIIA in our assay, a finding that, taken together with a preference for threonine at 299 (T299), suggests an explanation for the conservation of the motif N-S/G-T in IgG CH2 domains across virtually all species (see Fig. S1 ).
While our initial efforts, which focused on Fc␥RIIA, resulted in specificity for Fc␥RIIA and Fc␥RIIB at the expense of Fc␥RIIIA binding (see Fig. 2C ), the side-chain scanning data suggested that aglycosylated Fcs that bind Fc␥RIIIA with comparable affinity to WT could also be identified. Within the CЈ/E loop, rational design of double mutants based upon the weakly Fc␥RIIIA-binding N297D and N297H substitutions yielded variants that bound Fc␥RIIIA 176V at levels 10 to 40% of WT and with specificity for Fc␥RIIIA (see Fig. 5A ), a desired property in engineering Fcs with enhanced immune effector functions (2) . In a separate strategy, the consensus mutations K326E, K290E, and K290N-identified in a separate screen for improved Fc␥RIIA binding (data not shown) and through the efforts of previous groups (26, 27) -were introduced into the T299A background. Incorporation of the K326E mutation, located at the base of the F/G loop, led to enhanced binding for Fc␥RIIIA, approaching WT levels for Fc␥RIIIA 176V and weakly binding Fc␥RIIIA 176F (see Fig. 5B ). This result suggests that additional second-site mutations at contact interfaces other than the CЈ/E loop can lead to aglycosylated Fc␥RIIIA-and Fc␥RIIA-binding Fcs with a range of affinities and specificities.
Discussion
Until this study, the general knowledge of the binding interaction between IgG and Fc␥Rs indicated a dependence on the N-linked glycan attached to asparagine 297 on the IgG heavy chain. The Fc variants described in this article clearly demonstrate that glycosylation is not a strict requirement for Fc␥R engagement, either in vitro or in vivo. In an initial strategy, by generating aglycosylated Fc variants that bind to Fc␥RIIA and Fc␥RIIB, we could demonstrate that the set of mutations necessary to switch from a WT glycosylated binder to a functionally aglycosylated binder is fairly small; in our case it involved the introduction of only two point mutations. In a second more directed screening strategy, we could further demonstrate that by introducing additional modifications into our aglycosylated mutants, we can combine features from single mutants discovered from different screenings, thereby modulating the overall affinity features of the IgG variant. This combinatorial behavior of the contribution of single mutations is of special interest for the engineering of IgG variants with very well-defined binding properties.
In addition to the enhanced Fc␥RIIA 131R binding observed in the aglycosylated S298G/T299A variant, we were able to restore binding to Fc␥RIIIA 176V to near WT levels, suggesting that /T299A  N297Q  T299A  T299A/K326E  T299A/K290E  T299A/K290N  K290E/T299A/K326E  K290N/T299A/K326E  K326E  K290E  K290N  K290E/K326E  K290N/ further engineering can also lead to aglycosylated variants with WT or improved binding to Fc␥RIIIA. In particular, we anticipate that introducing mutations into the T299A background, which weakly binds both Fc␥RIIA and Fc␥RIIIA, will lead to fully Fc␥R competent aglycosylated antibody variants. Building upon these aglycosylated Fc␥RIIIA-binding variants will be essential for their potential use as cytotoxic antibodies, which have emerged as a promising class of therapeutics for treatment of human cancer in recent years (28) . Support for a critical role for Fc␥R engagement in the mechanism of antitumor activity, and specifically for Fc␥RIIIA, has come from three independent studies, which found a strong, positive correlation between patient response and the presence of specific alleles of the activating Fc␥R Fc␥RIIIA that conferred enhanced binding for the IgG1 Fc domain of the antibody (29) (30) (31) . While the S298G/ T299A variant does not bind complement, the above studies, as well as murine models that demonstrate a dominant role for Fc␥R engagement in therapeutic antibody activity (3), suggest that restoration of complement binding would be unnecessary for engineered Fc variants. In addition to their ability to bind Fc␥R, it will also be important to assess the stability of these variants, as previously characterized Fc variants (32) and deglycosylated WT Fc (33) have displayed reduced thermal stability.
Given the small number of mutations required to achieve N-linked glycosylation-independent Fc␥R binding, it is striking that all naturally occurring IgGs nevertheless use this posttranslational modification. Among different antibodies there is variation in the fucose and galactose-sialic acid attached to the core glycan structure (Fig. S6) , and it has been reported that these variations dramatically influence the antibody activity. The absence of fucose in the glycan was reported to enhance the affinity of Fc␥RIIIA for IgG up to 50-fold (13), thereby switching the antibody into an inflammatory mode. This is required, for example, for cytotoxic antibodies, but also occurs when autoantibodies generate pathogenic immune complexes and activate autoimmune cascades. In contrast to fucose, the presence of terminal sialic acid was demonstrated to be the critical factor for the anti-inflammatory action of high-dose intravenous Ig (12, 34) . Sialic acid reduces the affinity of Fc␥Rs to IgG by 5-to 10-fold (12) and, in addition, marks IgGs and subsequently allows them to bind to non-FcR lectins (34) and mediate downstream actions through these unique interactions, resulting in anti-inflammatory responses, including the up-regulation of Fc␥RIIB on effector macrophages (35) . The conservation of the N-S/G-T glycosylation motif among different species (Fig. S1 ) at the expense of this posttranslational variability supports the view that the glycan, although not necessarily required for Fc␥R binding, serves as a platform for further modulation of the IgG's activity, enabling posttranslational switching or tuning of the IgG function between an anti-inflammatory or inflammatory mode.
Finally, our demonstration that IgG variants that have uncoupled Fc␥R binding from N-linked glycosylation can be generated opens up unique possibilities for protein engineering and biomanufacture. Our results suggest that receptor binding affinity and specificity can be engineered on the simpler template of an unmodified polypeptide chain, and these properties can be selected by yeast surface display of aglycosylated Fc mutant libraries. Such mutants could then be produced in essentially any recombinant expression system without loss of the desired altered effector functions.
Materials and Methods
Library Construction. Libraries were constructed by homologous recombination of a mutated heavy-chain constant-region insert into the 4m5.3 heavychain yeast-secretion vector template according to previously published methods (36) . The 4m5.3 heavy-chain secretion vector was previously constructed from the pRS316 shuttle vector by insertion of the GAL10 promoter and alpha terminator, signal peptide, and 4m5.3 variable heavy-chain domain upstream of the hIgG1 CH1 to CH3 constant domains (Rakestraw JA, S.L.S., Piatesi A, Antipov E, K.D.W., unpublished data). Preparation of mutagenic CЈ/E loop gene inserts and digested template vector are detailed in SI Materials and Methods. Gene inserts were transformed with digested template vector by electroporation into the yeast strain YVH10/LC, a derivative of the yeast strain YVH10, containing a chromosomally integrated copy of the 4m5.3 light-chain yeast-secretion vector. The 296 -299 and 297-300 saturation libraries had Ϸ6 ϫ 10 7 transformants, 60-fold greater than their theoretical diversity at the DNA level (32 4 Ϸ 1.0 ϫ 10 6 ); the 297-299 library had Ϸ4 ϫ 10 7 transformants.
Oligonucleotides. Oligonucleotides are detailed in SI Materials and Methods.
Library Screening. Library screening was performed using the cell-surface secretion assay (CeSSA) (22) . Briefly, libraries were grown in SD-CAA (2% glucose, 0.67% yeast nitrogen base, 0.54% Na2HPO4, 0.86% NaH2PO4⅐H2O, 0.5% casein amino acids) at 30°C to an OD600 of Ϸ5, and then induced in YPG (2% galactose, 2% peptone, 1% yeast extract, 0.54% Na 2HPO4, 0.86% NaH2PO4⅐H2O) for 12 h at 20°C. Following this preinduction phase, yeast were labeled with fluorescein-PEG-NHS (Nektar) and reinduced in YPG containing 15% PEG (wt/vol) at 20°C for 36 h. Cells were washed with PBS containing 0.1% (wt/vol) BSA (PBS/BSA) and labeled with biotinylated hFc␥RIIA 131R preloaded onto streptavidin-Alexa 647 (Invitrogen). The library was sorted on a BD FACSAria (Becton Dickinson) and collected cells grown in SD-CAA supplemented with penicillin/streptomycin (Invitrogen), for a total of three rounds of screening. Library populations were labeled at increasingly stringent concentrations of Fc␥RIIA tetramer as follows: round one (50-nM Fc␥RIIA tetramer), round two (2-nM Fc␥RIIA tetramer), and round three (80-pM Fc␥RIIA tetramer). All clones isolated from screening were retransformed into YVH10/LC and individually assayed for Fc␥RIIA binding.
Site Directed Mutagenesis. Site-directed mutagenesis is detailed in SI Materials and Methods.
Characterization of Yeast-Secreted Fc Mutants. Fc mutants freshly transformed into YVH10/LC were grown in 5-ml SD-CAA at 30°C until an OD600 Ϸ5, then induced in 5-ml YPG at 20°C for 72 h. Cell-culture supernatants were loaded onto fluorescein-conjugated yeast overnight at 4°C; yeast were then washed with PBS/BSA, labeled with 10 nM of biotinylated Fc␥R preloaded onto streptavidin-Alexa 647 at 4°C for Ͼ2 h, and analyzed by flow cytometry. Labeling with 10-g/ml Protein A-Alexa 647 (Invitrogen) was performed as a separate IgG loading control for all samples.
Mice. ␥ Ϫ/Ϫ Fc␥RIIB Ϫ/Ϫ mice were generated in the Ravetch laboratory, backcrossed for 12 generations to the C57BL/6 background, and crossed to hFc␥RIIA tg mice (The Jackson Laboratory). Female mice at 2 to 4 months of age were used for the experiments and maintained at the Rockefeller University animal facility. All experiments were performed in compliance with federal laws and institutional guidelines and have been approved by the Rockefeller University.
Cell Culture. CHO cells were cultured according to the American Type Culture Collection guidelines. CHO-hFc␥RIIA 131H , CHO-hFc␥RIIA 131R , and hFc␥RIIB were obtained by transfection of the pCMV-Script-hFc␥RIIA 131H , CHOhFc␥RIIA 131R , and hFc␥RIIB plasmids and subsequent selection with 1-mg/ml geneticin (Invitrogen).
Antibodies and Recombinant Proteins. The 6A6-human Fc chimeric variants and soluble hFc␥-receptors were produced by transient transfection of 293T cells and subsequent purification from culture supernatants. For protein production, cells were cultured in DMEM supplemented with 1% Nutridoma SP (Roche). Cellculture supernatants were harvested 6 days after transfection, and protein was precipitated by ammonium sulfate precipitation. The 4m5.3-human Fc chimeric variants were produced by transient transfection of 293F cells (Invitrogen) and subsequent purification from cell-culture supernatants. For protein production, cells were cultured in Freestyle 293F Expression Medium (Invitrogen). Recombinant receptors were purified with Ni-NTA (Qiagen) and recombinant antibodies were purified with protein G Sepharose (GE Healthcare) or immobilized protein A (Pierce) by affinity chromatography. All proteins were dialyzed against PBS. Purity was assessed by SDS/PAGE followed by Coomassie Blue staining.
Immune Complex Binding Assay. For studying immune complex binding to surface Fc␥Rs, ICs were generated by incubating 10 g of the respective 4m5.3 (anti-FITC) chimera with 10 g of BSA-FITC (Sigma) in 1-ml PBS for 2 h at 37°C while shaking gently. CHO cells were stained for 2 h at 4°C with 1 g, 0.5 g, 0.2 g, or 0.1 g of ICs, washed with PBS and analyzed by FACS analysis.
Surface Plasmon Resonance Analysis. To determine the interaction between soluble hFc␥-receptors RIa (R&D Systems), Fc␥RIIA 131H , Fc␥RIIA 131R , Fc␥RIIB, Fc␥RIIIA, CIq (Calbiochem), and 4m5.3 antibody chimera, steady-state affinity measurements on a Biacore T100 biosensor were performed. Antibodies were immobilized at high densities to CM5 sensor chips (Biacore) by standard amine coupling. Soluble hFc␥-receptors were injected in five different concentrations through flow cells at room temperature in HBS-EP running buffer (Biacore) for 3 min at a flow rate of 30 l/min and dissociation was observed for 10 min. K d values were calculated after subtraction of background binding to a control flow cell using Biacore T100 Evaluation software.
Lectin Blot. Lectin blotting is detailed in SI Materials and Methods.
In Vivo Model Systems. Mice were injected intravenously with 50-g 6A6-hFc1 WT, N297A, or S298G/T299A in 100-l PBS. Platelet counts were determined before injection and at 4, 24, and 72 h after injection by blood collection of 50 l from the retro-orbital plexus and measuring platelet counts of a 1:10 dilution in PBS/5% BSA in an Advia 120 hematology system (Bayer). Platelet clearance for mice treated with each 6A6-hIgG1 variant was analyzed 4 h after injection by a one-way ANOVA test using SIGMASTAT. Error bars represent the standard deviation of three mice per group.
Computational Modeling. Computational modeling is detailed in SI Materials and Methods.
